Drugs / Lactobacillus johnsonii N6.2
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT03961347 Comparator | Feb 2020 → Mar 2026 | type 1 diabetes mellitus | University of Florida | Completed | No outcome recorded |
| Phase 2 | NCT03961854 Comparator | Oct 2019 → Jan 2026 | type 1 diabetes mellitus | University of Florida | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lactobacillus johnsonii N6.2 | “The probiotic Lactobacillus johnsonii N6.2 may prevent or restore the gut flora and show systemic impacts and adaptive immunity in the T1D population thereby preserving beta...” NCT03961854 ↗1“The probiotic Lactobacillus johnsonii N6.2 may prevent or restore the gut flora and show systemic impacts and adaptive immunity in the T1D population thereby preserving beta...” NCT03961347 ↗ |
| Modality | Other / unclassified | “The probiotic Lactobacillus johnsonii N6.2” NCT03961347 ↗ |